Isolate (product)

Isolate is a highly refined crystalline solid or powder containing ≥99% of a single cannabinoid — most commonly CBD, but also CBN, THCA, CBG, and delta-8 THC. It is produced by extraction followed by distillation, chromatography, and crystallization or winterization to remove all other cannabinoids, terpenes, flavonoids, waxes, lipids, and plant material. Finished isolate is typically odorless, tasteless, white or off-white, and sold as loose crystalline powder or as pressed "slabs" milled into powder. Regulatory treatment of isolate has become rapidly consequential. California AB 8 (Chapter 248, Statutes of 2025), effective January 1, 2026, bars industrial hemp raw extract from incorporation into food, beverages, or dietary supplements unless it is CBD or CBN isolate greater than 99% purity with no THC and no synthetic cannabinoids. Effective January 1, 2028, CBD isolate is explicitly excluded from California's "cannabis concentrate" definition — the first state-level codification of a ≥99% purity threshold. ⚠️ A pending 2026 cleanup bill, AB 2250, would add CBN isolate to the 2028 exclusion; it has not yet been enacted as of April 2026. The November 2025 Farm Bill amendment (P.L. 119-37, §781), enacted November 12, 2025, redefines hemp under 7 U.S.C. §1639o to use total THC (expressly including THCA) at ≤0.3% dry weight rather than delta-9 alone; it also caps final hemp-derived cannabinoid products at 0.4 mg total THC per container and excludes synthetically produced cannabinoids from the hemp definition. The amendment takes effect November 12, 2026 (one year after enactment) and will substantially narrow the legal space for THCA isolate and high-purity hemp-derived products. Multiple repeal and delay bills are pending in Congress but had not advanced as of April 2026. Trump Executive Order 14370 (December 18, 2025) directs the administration to work with Congress to narrowly revise §781 so "appropriate full-spectrum CBD products" can remain available; the EO is non-self-executing and has produced no statutory change to date. ⚠️ Delta-8 isolate occupies contested regulatory territory. Natural delta-8 in hemp is trace; commercial delta-8 is chemically converted from hemp-derived CBD using acids and solvents. The DEA (2021, and the 2023 Boos letter) positions "synthetically derived" THCs as Schedule I, while the Ninth Circuit in AK Futures LLC v. Boyd Street Distro, LLC, 35 F.4th 682 (2022), held that hemp-derived delta-8 fits the 2018 Farm Bill hemp definition. AK Futures remains good law as of April 2026, but §781's effective date in November 2026 will statutorily pull delta-8 back under CSA control, largely mooting AK Futures for post-November-2026 conduct. THCA isolate faces a parallel problem: DEA states that THCA does not meet the definition of legal hemp because total-THC accounting includes THCA. Industry usage treats isolate as a bulk white crystalline powder (~990 mg/g CBD), testing ≥99% on Certificate of Analysis and non-detectable for THC, serving as raw ingredient for tinctures, edibles, topicals, cosmetics, and vape carts. "Terpsolate" is isolate re-infused with terpenes for dabbing. Distinguishing characteristics relative to distillate include crystalline solid state (not oil), ≥99% single-cannabinoid purity versus distillate's 70–90%, the absence of any entourage effect, and flavorless, odorless, precisely dosable form. → See also: Distillate, Diamonds, Concentrate, Extract